(CAH) Cardinal Health, Inc. Company Overview

What does Cardinal Health do?

Cardinal Health, Inc. is a healthcare services and products company whose core role is to move medicines, medical products, radiopharmaceuticals, and supply-chain services through the healthcare system. The company describes itself as a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities on its investor-relations overview. In practical terms, Cardinal Health sits between manufacturers and care-delivery sites: pharmacies, hospitals, health systems, physician offices, ambulatory surgery centers, laboratories, and patients receiving supplies at home.

What business is this, in plain English?

Cardinal Health is best understood as a healthcare infrastructure company. It does not mainly earn money by discovering drugs or selling insurance. It earns small margins on very large volumes of healthcare products, and it layers higher-value specialty, logistics, data, pharmacy, and practice-management services on top of that distribution base. The company’s FY2025 Form 10-K says Cardinal Health provides medical products, pharmaceuticals, and solutions that improve healthcare supply-chain efficiency.

How does Cardinal Health make money?

Cardinal Health makes money through three connected economics engines: pharmaceutical and specialty distribution, medical products manufacturing and distribution, and a group of growth businesses now reported as Other. The revenue base is dominated by Pharmaceutical and Specialty Solutions, but the margin story is more nuanced. In FY2025, the Pharma segment produced $204.6B of segment revenue, while Other produced $5.4B of segment revenue but much higher segment profit margin.

Which segment generates the most revenue?

Pharmaceutical and Specialty Solutions is the main revenue engine. The segment distributes branded, generic, specialty, over-the-counter, and consumer healthcare products; maintains prime-vendor relationships; serves manufacturers with distribution and chargeback administration; and provides specialty support, patient access, consulting, and physician-practice services. The segment’s revenue is enormous because branded pharmaceuticals are expensive and pass through the distributor at low margin. That is why Cardinal Health can report more than $200B of annual Pharma revenue while consolidated gross margin remains below 5%.

Where do the higher-margin growth businesses fit?

Other includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. In the 2025 10-K, Cardinal Health explains that Nuclear and Precision Health Solutions operates nuclear pharmacies and manufacturing facilities, at-Home Solutions serves patients with chronic conditions through Edgepark and business-to-business distribution, and OptiFreight supports healthcare shipping needs through integrated technology solutions. These businesses are smaller than Pharma, but they help shift the portfolio toward services, data, specialized logistics, and patient-channel exposure.

Which segments and revenue streams matter most?

The key mistake in analyzing Cardinal Health is to rank the segments only by revenue. Pharma is the economic foundation, but it operates on thin margins and depends on customer contracts, generic sourcing, and manufacturer service economics. GMPD is strategically important because it provides Cardinal Health brand medical products, but its earnings have been pressured by manufacturing costs, tariffs, supply-chain complexity, and past goodwill impairment issues. Other is smaller but has the best disclosed segment margin and has become the main growth platform.

How concentrated is the customer and supplier base?

Customer concentration is a central feature of the model. In FY2025, CVS Health accounted for 30% of Cardinal Health revenue, and the five largest customers accounted for 43%. The company also disclosed that members of its two largest group-purchasing organization relationships, Vizient and Premier, collectively accounted for 27% of revenue. Supplier concentration is meaningful too: products from the five largest suppliers accounted for 37% of FY2025 revenue, and the largest supplier’s products accounted for about 9%. That concentration can help procurement efficiency, but it raises contract-renewal and bargaining-power risk.

What does the segment mix say about strategy?

The portfolio is moving toward specialty care, chronic-condition home supply, nuclear medicine, and logistics services. That does not replace the core distribution model; it complements it. Cardinal Health still needs the scale, manufacturer relationships, and customer reach of Pharma, but growth businesses give management additional ways to improve gross margin, diversify profit, and create more service-like economics.

What does the latest quarter show?

The latest official reporting period is the quarter ended March 31, 2026. Cardinal Health's Q3 FY2026 Form 10-Q and Q3 FY2026 earnings release reported revenue of $60.9B, GAAP operating earnings of $509M, net earnings attributable to Cardinal Health of $399M, and GAAP diluted EPS of $1.69. The same release reported non-GAAP operating earnings of $956M and non-GAAP diluted EPS of $3.17. The gap between GAAP and non-GAAP results matters because Q3 included a $184M pre-tax goodwill impairment related to the Navista and ION reporting unit.

Which latest-quarter line is most important?

The most important signal is the combination of revenue growth, segment profit growth, and guidance. Cardinal Health raised and narrowed FY2026 non-GAAP diluted EPS guidance to $10.70 to $10.80 and raised adjusted free cash flow guidance to $3.3B to $3.7B. That suggests management saw the Q3 performance as durable enough to upgrade the year, despite tariffs pressuring GMPD and the Navista and ION impairment depressing GAAP operating earnings.

What turning points shaped Cardinal Health's current strategy?

Cardinal Health’s history explains the current portfolio: drug distribution scale, medical-products exposure, generic sourcing, specialty services, and newer at-home and MSO platforms.

1. 1971
   Robert D. Walter purchased Monarch Foods and created a distribution company called Cardinal Foods. The origin matters because logistics scale, not product invention, became the recurring strategic capability.
2. 1980
   The purchase of Bailey Drug Company moved the business toward drug distribution, the foundation of today’s revenue model.
3. 1994
   Cardinal Distribution became Cardinal Health, reflecting the shift from a distribution identity into a broader healthcare-services company, as described in the official 50th-anniversary timeline.
4. 1999
   The Allegiance acquisition added hospital supplies such as drapes, gowns, gloves, and related products, shaping the GMPD platform.
5. 2003
   The Syncor acquisition made Cardinal Health a leading U.S. nuclear pharmacy services provider, a capability that still appears in Nuclear and Precision Health Solutions.
6. 2013
   AssuraMed and Wavemark expanded direct-to-patient supply and inventory-management technology, both relevant to at-Home Solutions and supply-chain services.
7. 2024-2025
   Specialty Networks, ION, GIA, Urology America, and ADS accelerated the move into specialty, MSO platforms, diabetes supplies, and provider services.

What did the 2025 acquisition cycle change?

FY2025 was unusually active. Cardinal Health disclosed acquisitions of ADS for about $1.1B, a 73% ownership interest in GIA for about $2.8B, Urology America for about $360M, ION for about $1.1B, and Specialty Networks for about $1.2B. These deals expanded higher-growth specialty and at-home businesses, but they also increased debt, intangible assets, amortization, acquisition-related compensation costs, and integration risk.

What gives Cardinal Health a competitive advantage?

Cardinal Health’s moat is not based on a single patent or consumer brand. It is based on scale, regulated distribution capabilities, customer integration, generic sourcing, product breadth, logistics reliability, and the difficulty of replacing a national healthcare supply-chain partner. The company’s filings also make clear that competition is intense, so the advantage is better described as operational durability rather than pricing freedom.

Why does distribution scale matter?

Healthcare distribution has high service expectations and thin percentage margins. A company must finance inventory, maintain compliant facilities, serve thousands of delivery points, manage manufacturer chargebacks and customer credits, and handle regulated products. Scale helps spread technology, compliance, distribution-center, and manufacturer-contract costs across large volumes. It also helps Cardinal Health compete for prime-vendor relationships because customers need reliability, breadth, and service support.

Where is the moat weaker?

The same 2025 annual report lists McKesson, Cencora, Medline, Owens & Minor, regional distributors, self-warehousing chains, third-party logistics firms, specialty distributors, and direct manufacturer distribution as competitors. That means Cardinal Health has meaningful barriers to entry but not immunity from contract pressure. Large customers can negotiate aggressively, and product mix can dilute margins when branded pharmaceutical sales grow faster than higher-margin services.

How financially strong is Cardinal Health?

Cardinal Health’s financial profile is unusual: very large revenue, low gross margin, strong but working-capital-sensitive cash flow, acquisition-driven leverage, and negative shareholders’ equity caused by years of repurchases and accumulated charges. A simple revenue multiple is therefore not very informative. The right analysis focuses on gross margin dollars, segment profit, cash conversion, debt maturities, opioid settlement payments, and whether acquired specialty businesses can produce enough profit to justify the capital deployed.

How do cash flow and debt shape the story?

In FY2025, operating cash flow was $2.4B, while additions to property and equipment were $547M. That implies a simple free-cash-flow calculation of about $1.85B before considering acquisition spending and other uses. The company also deployed $5.3B for acquisitions, $765M for share repurchases, $494M for dividends, and $400M for debt repayment. Debt increased materially: total long-term obligations and other short-term borrowings were $8.5B at June 30, 2025, up from $5.1B one year earlier, reflecting debt issuance and an $800M term loan used around acquisitions.

What balance-sheet items deserve attention?

At March 31, 2026, Cardinal Health had $56.7B of total assets, $3.94B of cash, $18.0B of inventory, $37.8B of accounts payable, $8.25B of long-term obligations excluding the current portion, and a $2.67B shareholders’ deficit. The negative equity balance does not automatically mean insolvency, but it limits the usefulness of book-value metrics. For a distributor, the more useful questions are whether liquidity is sufficient, whether debt is manageable against cash generation, and whether working-capital volatility remains controlled.

Who owns Cardinal Health stock, and why does governance matter?

Cardinal Health has a dispersed public-company ownership profile rather than founder control. Its proxy states that each common share carries one vote, and that 237,582,682 common shares were outstanding at the September 8, 2025 record date. That makes the investor base institutionally influenced: large passive holders, proxy voting policies, board oversight, compensation design, and capital allocation all matter.

The 2025 proxy statement also says the CEO’s stock ownership requirement is six times base salary, the CFO’s and segment CEOs’ requirement is four times, and other executive officers’ requirement is three times. That matters because Cardinal Health’s strategy involves acquisition risk, debt financing, litigation cash payments, and long-term operating turnaround work, all of which require incentives beyond one-year revenue growth.

What does the investor profile imply?

Because there is no founder with dominant voting control, management credibility is tied to execution. Investors will likely focus on whether acquisitions generate durable growth, whether GMPD improves after tariff and manufacturing-cost pressure, whether opioid settlement payments remain manageable, and whether share repurchases are balanced with debt reduction. Governance is therefore less about control risk and more about capital discipline.

What opportunities could improve Cardinal Health's outlook?

The most important opportunity is mix improvement. Cardinal Health is not trying to turn into a high-margin software company; it is trying to make a very large distribution system more profitable and resilient by adding specialty, at-home, nuclear, logistics, data, and provider-service capabilities. If the company can grow those businesses faster than the core and integrate acquisitions well, small percentage-point improvements in gross margin and segment profit can create meaningful dollars.

How does FY2026 guidance frame the opportunity?

After Q3 FY2026, management guided to non-GAAP diluted EPS of $10.70 to $10.80, Pharma segment profit growth of 22% to 23%, and Other segment profit growth of 36% to 38%. Those are not trivial targets for a company of this scale. They imply that specialty, branded products, generics program performance, and growth businesses are large enough to offset pressure from interest expense, tariffs, acquisition costs, and product-mix dilution.

What strategic priorities should a student extract?

A strategy-class reading should focus on resource leverage: Cardinal Health uses distribution scale, supplier access, pharmacy and provider relationships, and regulatory capability to enter adjacent businesses where service, data, logistics, or specialty expertise can add margin.

What risks could weaken Cardinal Health's outlook?

Cardinal Health’s risks are company-specific and financially meaningful. They include large-customer concentration, supplier concentration, regulatory compliance, opioid settlement obligations, acquisition integration, goodwill impairment, tariffs and commodity costs in GMPD, pricing pressure, cybersecurity and data risks, and working-capital volatility. Because the company operates in regulated healthcare distribution, risk is not a side issue; it is part of the economic model.

Which filing-sourced risk is most material?

Customer concentration is the easiest risk to connect to actual numbers. Cardinal Health’s FY2025 revenue declined 2%, largely because of the expiration of the OptumRx contracts, partly offset by branded and specialty pharmaceutical sales growth from existing and new customers. The company also says working-capital changes can vary significantly, and that the unwinding of negative working capital associated with the OptumRx contracts hurt FY2025 operating cash flow. For a distributor, the loss of a large low-margin contract can reduce revenue without destroying earnings, but it can still make growth rates, cash flow, and investor interpretation messy.

The company’s regulatory section in the annual report lists the DEA, FDA, CMS, state pharmacy boards, the NRC, EPA, FTC, Customs and Border Protection, and comparable foreign agencies. That breadth means compliance risk spans controlled substances, medical-device manufacturing, nuclear pharmacies, radiopharmaceuticals, import controls, privacy, and environmental matters. The annual report also notes ethylene oxide emissions litigation and regulatory actions could affect procurement and supply continuity.

Which KPIs matter most for Cardinal Health analysis?

The most useful KPIs are not just revenue and EPS. For Cardinal Health, analysts should track segment profit by business, gross margin rate, generic-program contribution, specialty growth, GMPD margin, working capital, operating cash flow, adjusted free cash flow, capital deployment, customer concentration, and regulatory cash obligations. These metrics map directly to how the business creates or loses value.

Why does Cardinal Health matter for valuation work?

For DCF work, top-line growth is not enough. A model should separate low-margin distribution growth from higher-margin specialty and service growth; model gross-margin rate carefully; treat working capital as volatile; include capex; and reflect opioid settlement payments and acquisition debt. Terminal value should stay disciplined because healthcare distribution is competitive and regulated.

What should students and investors monitor next?

The watchlist is straightforward: Pharma segment profit growth versus the 22% to 23% FY2026 guidance, Other segment profit growth versus the 36% to 38% guidance, GMPD margin after tariff pressure, gross margin rate, nine-month and full-year free cash flow, acquisition-related amortization and compensation costs, debt reduction, opioid settlement cash payments, and any change in major customer or supplier relationships. Those items will explain more than a single headline revenue number.

What is the key takeaway from Cardinal Health analysis?

Cardinal Health is important because it is a scaled piece of healthcare infrastructure, not because it has a glamorous margin profile. It moves essential products through a regulated system, serves large healthcare customers, and is trying to use that base to build higher-growth specialty, home-care, nuclear, logistics, data, and practice-management businesses. Its core strength is scale and execution; its core constraint is thin-margin, contract-sensitive distribution.

The FY2025 earnings release and annual report showed $222.6B of revenue, $8.2B of gross margin, $2.3B of GAAP operating earnings, and $2.4B of operating cash flow. Q3 FY2026 then showed renewed revenue growth, stronger non-GAAP operating earnings, upgraded EPS and adjusted free-cash-flow guidance, but also a goodwill impairment, higher interest expense, acquisition costs, and GMPD tariff pressure.